LLY

939

-4.36%↓

JNJ

240.93

-0.32%↓

ABBV

222.23

+0.48%↑

NVS

154.79

+0.41%↑

AZN

191.77

+0.09%↑

LLY

939

-4.36%↓

JNJ

240.93

-0.32%↓

ABBV

222.23

+0.48%↑

NVS

154.79

+0.41%↑

AZN

191.77

+0.09%↑

LLY

939

-4.36%↓

JNJ

240.93

-0.32%↓

ABBV

222.23

+0.48%↑

NVS

154.79

+0.41%↑

AZN

191.77

+0.09%↑

LLY

939

-4.36%↓

JNJ

240.93

-0.32%↓

ABBV

222.23

+0.48%↑

NVS

154.79

+0.41%↑

AZN

191.77

+0.09%↑

LLY

939

-4.36%↓

JNJ

240.93

-0.32%↓

ABBV

222.23

+0.48%↑

NVS

154.79

+0.41%↑

AZN

191.77

+0.09%↑

Search

Simulations Plus Inc

Abierto

SectorSanidad

12.09 -1.47

Resumen

Variación precio

24h

Actual

Mínimo

11.88

Máximo

12.4

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+56.77% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.40%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-118M

250M

Apertura anterior

13.56

Cierre anterior

12.09

Noticias sobre sentimiento de mercado

By Acuity

11%

89%

11 / 351 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 mar 2026, 21:37 UTC

Adquisiciones, fusiones, absorciones

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Noticias de Eventos Importantes

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Charlas de Mercado

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Charlas de Mercado

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Adquisiciones, fusiones, absorciones

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Noticias de Eventos Importantes

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Charlas de Mercado

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Noticias de Eventos Importantes

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Charlas de Mercado

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Charlas de Mercado

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Charlas de Mercado

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Noticias de Eventos Importantes

Trump Ends News Conference

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

56.77% repunte

Estimación a 12 Meses

Media 19 USD  56.77%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

11 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat